AAAAAA

   
Results: 1-13 |
Results: 13

Authors: de Sevaux, RGL Gregoor, PJHS Hene, RJ Hoitsma, AJ Vos, P Weimar, W van Gelder, T Hilbrands, LB
Citation: Rgl. De Sevaux et al., A controlled trial comparing two doses of cyclosporine in conjunction withmycophenolate mofetil and corticosteroids, J AM S NEPH, 12(8), 2001, pp. 1750-1757

Authors: ter Meulen, CG Gregoor, PJHS Weimar, W Hilbrands, LB
Citation: Cg. Ter Meulen et al., Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone, TRANSPLAN I, 14(2), 2001, pp. 99-102

Authors: Gregoor, PJHS Zietse, R van Saase, JLCM op de Hoek, CT Ijzermans, JNM Lavrijssen, ATJ de Jong, GMT Kramer, P Weimar, W
Citation: Pjhs. Gregoor et al., Immunosuppression should be stopped in patients with renal allograft failure, CLIN TRANSP, 15(6), 2001, pp. 397-401

Authors: van Besouw, NM van der Mast, BJ de Kuiper, P Gregoor, PJHS Vaessen, LMB IJzermans, JNM van Gelder, T Weimar, W
Citation: Nm. Van Besouw et al., T-cell reactivity during azathioprine therapy compared with mycophenolate mofetil therapy, TRANSPLAN P, 33(3), 2001, pp. 2239-2240

Authors: van der Mast, BJ van Besouw, NM de Kuiper, P Vaessen, LMB Gregoor, PJHS IJzermans, JNM van Gelder, T Claas, FHJ Weimar, W
Citation: Bj. Van Der Mast et al., Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression., TRANSPLANT, 72(5), 2001, pp. 873-880

Authors: Gregoor, PJHS van Gelder, T Weimar, W
Citation: Pjhs. Gregoor et al., Mycophenolate mofetil, Cellcept (R), a new immunosuppressive drug with great potential in internal medicine, NETH J MED, 57(6), 2000, pp. 233-246

Authors: van Gelder, T Gregoor, PJHS Weimar, W
Citation: T. Van Gelder et al., Switching antiretroviral therapy from an enzyme-inducing drug, THER DRUG M, 22(5), 2000, pp. 639-639

Authors: van Besouw, NM van der Mast, BJ de Kuiper, P Gregoor, PJHS Vaessen, LMB Ijzermans, JNM van Gelder, T Weimar, W
Citation: Nm. Van Besouw et al., Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced, TRANSPLANT, 70(1), 2000, pp. 136-143

Authors: Gregoor, PJHS van Gelder, T van Besouw, NM van der Mast, BJ Ijzermans, JNM Weimar, W
Citation: Pjhs. Gregoor et al., Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction, TRANSPLANT, 70(1), 2000, pp. 143-148

Authors: Gregoor, PJHS van Gelder, T Hesse, CJ van der Mast, BJ van Besouw, NM Weimar, W
Citation: Pjhs. Gregoor et al., Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study, NEPH DIAL T, 14(3), 1999, pp. 706-708

Authors: van Besouw, NM van der Mast, BJ Gregoor, PJHS Hesse, CJ IJzermans, JNM van Gelder, T Weimar, W
Citation: Nm. Van Besouw et al., Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels, NEPH DIAL T, 14(11), 1999, pp. 2710-2713

Authors: Gregoor, PJHS van Gelder, T van der Ende, ME Ijzermans, JNM Weimar, W
Citation: Pjhs. Gregoor et al., Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors, TRANSPLANT, 68(8), 1999, pp. 1210-1210

Authors: Gregoor, PJHS de Sevaux, RGL Hene, RJ Hesse, CJ Hilbrands, LB Vos, P van Gelder, T Hoitsma, AJ Weimar, W
Citation: Pjhs. Gregoor et al., Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients, TRANSPLANT, 68(10), 1999, pp. 1603-1606
Risultati: 1-13 |